Live price temporarily unavailable.
C4 Therapeutics (CCCC) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Growth (year over year) | — | — | — | −32.1% | −33.3% | +71.4% | +1.0% |
| Operating income | −$35.5M | −$60.4M | −$82.1M | −$129.5M | −$139.0M | −$119.6M | −$115.2M |
| Operating margin | — | — | −179.4% | −416.6% | −669.8% | −336.1% | −320.5% |
| Net income | −$34.1M | −$66.3M | −$83.9M | −$128.2M | −$132.5M | −$105.3M | −$105.0M |
| Net margin | — | — | −183.2% | −412.2% | −638.3% | −296.0% | −292.1% |
| EPS (diluted) | −$31.03 | −$5.83 | −$1.82 | −$2.62 | −$2.67 | −$1.52 | −$1.27 |
| Balance sheet | |||||||
| Cash and equivalents | $90.5M | $181.7M | $76.1M | $29.8M | $126.6M | $55.5M | $74.6M |
| Total assets | $118.3M | $400.1M | $506.8M | $430.8M | $376.5M | $349.6M | $359.1M |
| Total liabilities | $119.2M | $119.3M | $117.2M | $141.6M | $130.3M | $133.6M | $102.5M |
| Long-term debt | — | $10.1M | $10.8M | $9.20M | $0 | — | — |
| Shareholders' equity | −$112.0M | $280.8M | $389.6M | $289.2M | $246.1M | $216.0M | $256.6M |
| Cash flow | |||||||
| Operating cash flow | $55.6M | −$67.2M | −$87.0M | −$105.9M | −$106.8M | −$65.2M | −$98.7M |
| Capital expenditure | $1.35M | $650.0K | $1.28M | $5.50M | $1.71M | $180.0K | $607.0K |
| Free cash flow | $54.3M | −$67.9M | −$88.2M | −$111.4M | −$108.5M | −$65.3M | −$99.3M |
| Share buybacks | $30.0K | $194.0K | — | $0 | $110.0K | $194.0K | $193.0K |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $15.4M | $5.18M | $7.24M | $6.46M | $11.2M | $11.0M | $6.15M | $6.64M |
| Growth (year over year) | +38.7% | +58.8% | +138.2% | −46.2% | −26.9% | +112.8% | −15.0% | +2.8% |
| Operating income | −$28.2M | −$37.7M | −$29.2M | −$28.5M | −$34.4M | −$23.1M | −$27.8M | −$26.4M |
| Operating margin | −183.9% | −728.4% | −402.9% | −441.0% | −306.4% | −210.1% | −451.6% | −397.9% |
| Net income | −$24.7M | −$34.6M | −$26.3M | −$26.0M | −$32.2M | −$20.5M | −$25.1M | −$23.6M |
| Net margin | −160.6% | −667.8% | −363.7% | −402.6% | −286.4% | −186.0% | −408.5% | −355.9% |
| EPS (diluted) | −$0.35 | −$0.50 | −$0.37 | −$0.37 | −$0.44 | −$0.09 | −$0.20 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $59.6M | $55.5M | $51.3M | $78.2M | $58.8M | $74.6M | $61.3M | $78.6M |
| Total assets | $376.1M | $349.6M | $319.5M | $296.5M | $265.5M | $359.1M | $328.9M | $359.4M |
| Total liabilities | $133.4M | $133.6M | $124.4M | $122.5M | $111.1M | $102.5M | $94.6M | $112.1M |
| Shareholders' equity | $242.7M | $216.0M | $195.1M | $174.1M | $154.4M | $256.6M | $234.2M | $247.3M |
| Cash flow | ||||||||
| Operating cash flow | −$24.1M | −$17.9M | −$33.3M | −$12.1M | −$31.2M | −$22.1M | −$29.9M | −$1.57M |
| Capital expenditure | −$13.0K | −$4.00K | $0 | $185.0K | $411.0K | $11.0K | $64.0K | $37.0K |
| Free cash flow | −$24.1M | −$17.9M | −$33.3M | −$12.2M | −$31.6M | −$22.2M | −$30.0M | −$1.61M |
| Share buybacks | $85.0K | $0 | $155.0K | $0 | $24.0K | $14.0K | $200.0K | $0 |
From C4 Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning C4 Therapeutics in our feed yet.